• Cachexia is rapid, involuntary weight loss associated with many acute and chronic conditions, including HIV/AIDS, and it often confers increased morbidity and mortality • Previous rates of AIDS-related cachexia or wasting have been estimated as high as 53% of HIV patients 1-2 , depending on the definition of cachexia.
• To our knowledge, there have not been any published estimates of cachexia among patients diagnosed for HIV/AIDS in nationally representative databases
• To estimate the prevalence of cachexia diagnosis and treatment among patients with HIV/AIDS in a nationally representative database 
CONCLUSION:
In this database, 7-8% of all persons with HIV/AIDS were cachectic, based on diagnostic and treatment evidence. Approximately 8% of prevalent cachexia cases did not receive an indicated pharmacologic treatment. As many as one-third of prevalent cases (i.e., 572 of 1,734) cannot be ascertained through the use of ICD-9-CM diagnosis codes alone. This is not surprising, insofar as all patients in our sample have a diagnosis of HIV/AIDS and US payers generally require only one diagnosis code to effect claim payment. These findings underscore the importance of considering use of pharmacologic treatment in estimating prevalence of comorbid conditions in persons with chronic diseases. 
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Overview
• Retrospective cohort design
• Employed administrative billing and eligibility data from a large US managed care database
• Assessed the prevalence of cachexia diagnosis and treatment among patients diagnosed with HIV/AIDS
Study Database
• The Pharmetrics managed care database contains complete healthcare information for approximately 55 million patients from 75 managed-care organizations from all four U.S. geographical regions
• The standard extract from the Pharmetrics database consists of two files: a Claims Detail file and an Eligibility file.
• The Eligibility file contains patient-level details on monthly medical and pharmacy eligibility, year of birth, gender, and geographical region
• The Claims Detail file contains a number of specific elements for medical and pharmacy claims; key variables include:
• 
Patient Selection
• We identified all persons who had ≥1 paid claim listing a primary or secondary diagnosis of HIV/AIDS (ICD-9-CM 042) during calendar years [2004] [2005] • For inclusion in the study, patients were required to be eligible for medical and pharmacy benefits for the period beginning on January 1 of the calendar year in which they were diagnosed, and extending through the month of their diagnosis.
Study Measures and Data Analysis
• A concomitant diagnosis of cachexia was assumed if the patient also had ≥1 paid claim during the same calendar year as their HIV/AIDS claim listing a primary or secondary diagnosis of: Average age was 42 years: 57% were younger than 45 years and 43% were 45+ years of age Twenty-eight percent were female • Overall prevalence of cachexia was estimated at 1,734 persons, or 72.5 per 1,000 persons with HIV/AIDS • Of these: 134 (5.6 per thousand) had a cachexia diagnosis but no treatment, 572 (23.9 per thousand) had cachexia treatment but no diagnosis code, and 1,028 (43.0 per thousand) had a diagnosis code and were treated • Retrospective study design
Results
• Clinical measures (e.g., weight) not available in database which may explain why our estimated rates are somewhat lower than previously published findings • Lack of definition uniformity for cachexia across general medical practice
Limitations
• In this nationally-representative managed care database, 7-8% of all persons with HIV/AIDS were cachectic, based on diagnostic and treatment evidence • Approximately 8% of prevalent cachexia cases did not receive an indicated pharmacologic treatment • As many as one-third of prevalent cases (i.e., 572 of 1,734) cannot be ascertained through the use of ICD-9-CM diagnosis codes alone, therefore pharmacologic therapy is also an important marker for cachexia • This is not surprising, insofar as all patients in our sample have a diagnosis of HIV/AIDS and US payers generally require only one diagnosis code to effect claim payment • These findings underscore the importance of considering use of pharmacologic treatment in estimating prevalence of comorbid conditions in persons with chronic diseases
Summary and Conclusions
• Higher cachexia prevalence was observed among:
Persons aged 45+ years; and Males
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